Claritas Pharmaceuticals, Inc. Share Price

Stocks

CLAZ.F

CA1806342061

Biotechnology & Medical Research

OTC Markets Traded
Market Closed - 16:09:11 08/10/2026 BST 5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for Claritas Pharmaceuticals, Inc. -.--% -

Valuation: Claritas Pharmaceuticals, Inc.

Market Cap 5.37M 3.84M 3.43M 3.15M 2.86M 363M 5.5M 37.57M 15.11M 192M 14.4M 14.09M 608M P/E 2019
-0.74x
P/E 2020 0.13x
Enterprise Value 6.29M 4.49M 4.01M 3.69M 3.35M 426M 6.45M 44.01M 17.7M 225M 16.86M 16.5M 712M EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
99.74%
Yield 2019 *
-
Yield 2020 -
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0.3
10 years 0
Extreme 1.0E-6
15.31
Manager TitleAgeSince
Chief Executive Officer 76 20/06/2017
Director of Finance/CFO 58 28/06/2018
Director TitleAgeSince
Chairman 76 17/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
11/10/21 Buy 118,000 0.3332%
11/10/21 Buy 152,500 0.4307%
11/10/21 Buy 24,500 0.0692%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 37
-2.43%-4.38%+40.32%+55.64% 62.23B
+0.61%+1.10%+11.79%+70.22% 54.92B
+0.62%+2.74%+17.68%+103.81% 55.26B
+1.61%-3.30%+22.77%+33.16% 42.59B
-1.74%-3.02%+13.83%+93.17% 41.08B
+3.22%+4.30%+227.37%+776.49% 40.33B
+0.57%+25.47%+102.34%+88.40% 33.12B
-1.09%-0.05%+13.55%+45.35% 32.61B
-4.46%+9.98%-43.92%+320.28% 23.98B
Average -0.31%+3.07%+45.08%+176.28% 38.61B
Weighted average by Cap. -0.21%+2.12%+45.63%+159.79%

Financials

2019 2020
Net sales - -
Net income -21.21M -15.16M -13.54M -12.44M -11.3M -1.44B -21.75M -148M -59.72M -758M -56.89M -55.67M -2.4B 4.21M 3.01M 2.69M 2.47M 2.24M 285M 4.32M 29.47M 11.85M 150M 11.29M 11.05M 477M
Net Debt 704K 503K 449K 413K 375K 47.65M 722K 4.93M 1.98M 25.15M 1.89M 1.85M 79.71M 920K 657K 587K 539K 490K 62.27M 943K 6.44M 2.59M 32.86M 2.47M 2.41M 104M
Logo Claritas Pharmaceuticals, Inc.
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.
Employees
-
  1. Stock Market
  2. Stocks
  3. CLAZ.F Stock